Cancer Discov. 2021 Nov;11(11):2664-2665. doi: 10.1158/2159-8290.CD-NB2021-0382. Epub 2021 Sep 21.
The DESTINY-Breast03 study, a randomized, phase III trial pitting the antibody-drug conjugates trastuzumab emtansine and trastuzumab deruxtecan against each other in HER2+ metastatic breast cancer, found remarkable improvements in efficacy and safety for the latter, newer therapy.
DESTINY-Breast03研究是一项随机III期试验，在HER2阳性转移性乳腺癌中对比抗体药物偶联物曲妥珠单抗恩美曲妥珠单抗和曲妥珠单抗德曲妥珠单抗，结果发现，对于后一种更新的疗法，其疗效和安全性有显著改善。
